Heart FailurePhase 4STOP-MED CTRCDNCT06183437
The STOP-MED CTRCD Trial
A Phase 4 study testing Stopping Heart Failure Medication(s) in people with Heart Failure and Cardiotoxicity, run by Dinesh Thavendiranathan at 14 sites in 6 countries.
Trial summary
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Cardiotoxicity, Cardiac Toxicity
- What is being tested?
- Stopping Heart Failure Medication(s)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 335 participants
- Where
- 14 sitesin 6 countries
- Study dates
- 4 Mar 2024to Dec 2031
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (age ≥18 years) with cancer therapy completed more than 6 months prior (other than hormonal therapy) and no plan for further cancer treatments with potential risk for CTRCD.
- Prior cancer therapy with anthracyclines and/ or HER2-targeted therapy.
- Prior asymptomatic, moderate to severe CTRCD, defined using the ESC/ICOS criteria (MODERATE: ≥10% drop in LVEF from baseline to 40% to 49.9% OR <10% drop to 40-49.9% with a reduction in GLS by >15% or new abnormal Troponin I/T or NT-proBNP or SEVERE: new LVEF reduction to <40% from normal baseline LVEF), diagnosed within 1 year of completing potentially cardiotoxic cancer therapy.
- Current use of ≥1 HF medication started for CTRCD for at least 6 months with LVEF ≥50% by recently performed (≤6 months) echocardiogram, normal sex and age adjusted NT-proBNP or BNP ≤97.5th Centile, and no symptoms attributable to HF.
- Reference ranges for NT-proBNP and BNP by age and sex:
- <30 years: Female: NT-proBNP ≤196 pg/ml, BNP ≤55 pg/ml Male: NT-proBNP ≤104 pg/ml, BNP ≤29 pg/ml
Show all 14Show fewer
- 30-39 years: Female: NT-proBNP ≤209 pg/ml, BNP ≤59 pg/ml Male: NT-proBNP ≤102 pg/ml, BNP ≤29 pg/ml
- 40-49 years: Female: NT-proBNP ≤233 pg/ml, BNP ≤65 pg/ml Male: NT-proBNP ≤137 pg/ml, BNP ≤38 pg/ml
- 50-59 years: Female: NT-proBNP ≤299 pg/ml, BNP ≤84 pg/ml Male: NT-proBNP ≤195 pg/ml, BNP ≤55 pg/ml
- 60-69 years: Female: NT-proBNP ≤399 pg/ml, BNP ≤112 pg/ml Male: NT-proBNP ≤333 pg/ml, BNP ≤93 pg/ml
- 70-79 years: Female: NT-proBNP ≤743 pg/ml, BNP ≤208 pg/ml Male: NT-proBNP ≤763 pg/ml, BNP ≤214 pg/ml
- ≥80 years: Female: NT-proBNP ≤2,704 pg/ml, BNP ≤757 pg/ml Male: NT-proBNP ≤6,792 pg/ml, BNP ≤1,902 pg/ml
- Confirmation of LVEF ≥50% and normal volumes at baseline CMR (i.e., some patients recruited based on echocardiography, may be excluded if baseline CMR LVEF/volumes are not normal). This is included given that the primary outcome includes the use of CMR LVEF.
- Normal Ventricular end-diastolic volumes by CMR as defined by the Society of Cardiac Magnetic Resonance 2025 update.
Who cannot join
- Indication for continuation of HF medications i.e., ongoing HF symptoms, chronic kidney disease (CKD), vascular disease, atrial or ventricular arrythmias, other (note: participants with hypertension pre-CTRCD will continue their antihypertensive as only medication started for CTRCD will be ceased).
- Contraindications for CMR (e.g., MRI non-compatible implanted pacemakers).
- Patients with cardiac devices i.e. defibrillator, CRT, pacemaker, etc.
- Continued use of loop diuretic therapy for heart failure purposes i.e., furosemide.
- Life expectancy <1 year or metastatic disease.
- Prior history of major cardiovascular event (defined as myocardial infarction, cerebral vascular event, admission for HF) or therapeutic cardiovascular procedure (e.g., percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)).
- Issues that prevent communication, understanding or presentation for study-related visits and inability to provide informed consent.
Trial locations and contacts
14 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
14 sites in 6 countries
Canada6 sites, 6 recruiting
- Recruiting
Cardio-Oncology Clinic, MAHI, University of Alberta Hospital
Edmonton, Alberta, T6G 1C9
Gabor Gyenes, MD
Gabor Gyenes, MD
- Not yet recruiting
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
Darryl Leong, MD
Darryl Leong, MD
- Recruiting
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7
Ian Paterson, MD
Ian Paterson, MD
- Not yet recruiting
St Michael's Hospital
Toronto, Ontario, M5B 1W8
Kim Connelly, MD
Kim Connelly, MD
- Recruiting
University Health Network
Toronto, Ontario, M5G2C4
Paaladinesh Thavendiranathan, MD, 416-340-5326, dinesh.thavendiranathan@uhn.ca
Paaladinesh Thavendiranathan, MD
- Recruiting
St. Boniface Hospital
Winnipeg, Manitoba, R2H 2A6
Davinder Jassal, MD
Davinder Jassal, MD
United Kingdom3 sites, 3 recruiting
- Recruiting
Liverpool Heart and Chest Hospital
Liverpool, L14 3PE
Rebecca Dobson, MD, 44 151 600 1616, Rebecca.Dobson@lhch.nhs.uk
Rebecca Dobson, MD
- Recruiting
Barts Health NHS Trust, University College London
London, London
Charlotte Manisty, MD
Charlotte Manisty, MD
- Not yet recruiting
Guy's and St Thomas' NHS Foundation Trust (Royal Brompton Hospital)
London
Alexander Lyon, MD, 44 20 7352 8121
Alexander Lyon, MD
United States2 sites, 2 recruiting
- Recruiting
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Tomas Neilan, MD, TNEILAN@mgh.harvard.edu
Tomas Neilan, MD
- Not yet recruiting
University of California, Los Angeles
Los Angeles, California, 90095
Eric Yang, MD, 310-825-4321, EHYang@mednet.ucla.edu
Eric Yang, MD
Australia1 site, 1 recruiting
- Recruiting
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004
Tom Marwick, MD
Tom Marwick, MD
Poland1 site, 1 recruiting
- Not yet recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw
Anna Borowiec, MD, 48 22 546 20 00, Anna.Borowiec@nio.gov.pl
Anna Borowiec, MD
Spain1 site, 1 recruiting
- Not yet recruiting
La Paz University Hospital
Madrid, 28046
Teresa Lopez Fernandez, MD, +34 917 27 70 00, teresa.lopez@salud.madrid.org
Teresa Lopez Fernandez, MD
About this study
Official title: A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients With Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in >80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology.
To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
- Being tested
- Stopping Heart Failure Medication(s)
- Keywords
- cancer therapy related cardiac dysfunction
- Medical subject headings
- Heart Failure, Cardiotoxicity, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stopping Heart Failure Medication(s)Other
This group will stop their heart failure medication(s) under the supervision of the study team.
| Study group | Role | What they receive |
|---|---|---|
| Stop Group | Experimental | This group will stop their heart failure medication(s) under the supervision of the study team. The investigators expect most participants in the STOP group to only be on beta-blockers (BB) and/or angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The ACEi or ARB will be stopped first. The ACEi or ARB will be reduced by 50% every 7 days and stopped 7 days after 25% of maximal recommended dose for HF is reached. At this point (or at baseline if only on BB), the BB dose will be reduced by 50% every 7 days then stopped once 25% of the maximal dose is reached. Participants on 75% of the maximal dose will be reduced to 50% of the maximal dose before reducing by 50% every 7 days. Other HF medications will be stopped as follows: MRA: reduce by 50% every 7 days then stop once 50% of maximal dose is reached; SGLT2i: stopped without titration, ARNi: reduce by 50% every 7 days then stop once 25% of the maximal dose. Receives: Other: Stopping Heart Failure Medication(s) |
| Standard of Care Group | No intervention | This group with continue with their heart failure medication(s) for at least 1 year. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer Therapy Related Cardiac Dysfunction Relapse
To compare the proportion of those that develop by 1 year of follow-up one or both of the following (i) left ventricular ejection fraction <50% and an absolute decline of >5% from baseline by cardiac magnetic resonance (CMR) (ii) new heart failure signs (at least two physical findings or one physical finding and one laboratory finding) AND symptoms (at least one) with the initiation of qualifying heart failure therapy.
Measured: 1 year
Secondary outcomes (11)
Dichotomized Primary Outcome
The primary outcome stratified by baseline LVEF of 50-55% vs >55% .
Measured: 1 year
Moderate to severe CTRCD by 1 year
The development of moderate to severe asymptomatic CTRCD as per the 2022 ESC guidelines by 1 year follow-up.
Measured: 1 year
Changes in cardiac magnetic resonance parameters
Differences between the two groups in the following measures.
- Changes in CMR LVEF as a continuous parameter.
- Proportion of participants with increased CMR indexed LV volumes by ≥10% to higher-than-normal limits.
- Proportion of participants with decline in CMR LVEF to <50% with a >10% absolute fall compared to pre-HF medication withdrawal.
- CMR peak systolic global longitudinal strain (GLS) worsening by >15%.
Measured: 1 year
Left ventricular diastolic function
Proportion of participants with new diastolic dysfunction or worsening diastolic function ≥1 grade by echocardiography between the two study groups.
Measured: 1 year
Non-adherence of heart failure medication(s)
Proportion of participants with non-adherence of heart failure medication(s) by 1 year between the two study groups. Non-adherence is defined in the STOP group as the proportion of participants in whom successful cessation of all medications used to treat CTRCD was not possible or re-addition of the same medications used in that participant for HF was necessary for non-HF indications (e.g., palpitations). In the standard of care (SOC) group non-adherence is defined as the proportion of participants who stopped all HF medications used to treat CTRCD.
Measured: 1 year
N-terminal pro B-type Natriuretic Peptide (NT-pro BNP)
Doubling of NT-pro BNP compared to pre-HF therapy cessation between the two study groups.
Measured: 1 year
Changes in quality of life score
Difference in patient questionnaires scores between the two groups using the following patient questionnaires:
- Kansas City Cardiomyopathy Questionnaire
- Short Form (SF) Survey -36
- EQ-5D-5L
Measured: 1 year
Cost effectiveness analysis
We will compare the cost per quality adjusted life years between the two study groups.
Measured: 1 year
Proportion of participants developing the primary outcome by whether they developed moderate versus severe CTRCD at original diagnosis
The proportion of those that develop the primary outcome stratified by CTRCD LVEF <40% or ≥40%
Measured: 1 year
Incidence of novel biomarkers and genomic factors that may determine the risk of developing the primary endpoint
Incidence of cardiac, inflammatory, endothelial and other novel biomarkers and genomic factors that may determine the risk of developing the primary endpoint.
Measured: 1 year
Proportion of participants developing the primary outcome stratified by natriuretic peptides thresholds.
Proportion of participants developing the primary outcome stratified by natriuretic peptides thresholds.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2023
- Study start4 Mar 2024
- Primary completionDec 2027 (estimated)
- Study completionDec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 335 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dinesh Thavendiranathan
- Sponsor type
- University, hospital or other
- Collaborators
- Unity Health Toronto, Hamilton Health Sciences Corporation, St. Boniface Hospital, Ottawa Heart Institute Research Corporation, University College London Hospitals, Brigham and Women's Hospital, Baker Heart and Diabetes Institute, University of California, Los Angeles, Alberta Health services, Hospital Universitario La Paz, Liverpool Heart and Chest Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Maria Sklodowska-Curie National Research Institute of Oncology, Memorial Sloan Kettering Cancer Center
- Responsible party
- Sponsor-investigator, Dinesh Thavendiranathan, University Health Network, Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06183437
- Sponsor's protocol ID
- STOPMED-1
- Acronym
- STOP-MED CTRCD
- Status last verified
- Nov 2025
- First submitted
- 13 Dec 2023
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients With Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial
- ClinicalTrials.gov ID
- NCT06183437
- Acronym / sponsor ID
- STOP-MED CTRCD / STOPMED-1
- Keywords
- cancer therapy related cardiac dysfunction
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 335 participants (estimated)
- Lead sponsor
- Dinesh ThavendiranathanUniversity, hospital or other
- Collaborators
- Unity Health Toronto, Hamilton Health Sciences Corporation, St. Boniface Hospital, Ottawa Heart Institute Research Corporation, University College London Hospitals, Brigham and Women's Hospital, Baker Heart and Diabetes Institute, University of California, Los Angeles, Alberta Health services, Hospital Universitario La Paz, Liverpool Heart and Chest Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Maria Sklodowska-Curie National Research Institute of Oncology, Memorial Sloan Kettering Cancer Center
- Study start
- 4 Mar 2024 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2031 (estimated)
- First posted
- 27 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in >80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology.
To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stop Group | Experimental | Other: Stopping Heart Failure Medication(s)This group will stop their heart failure medication(s) under the supervision of the study team. The investigators expect most participants in the STOP group to only be on beta-blockers (BB) and/or angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The ACEi or ARB will be stopped first. The ACEi or ARB will be reduced by 50% every 7 days and stopped 7 days after 25% of maximal recommended dose for HF is reached. At this point (or at baseline if only on BB), the BB dose will be reduced by 50% every 7 days then stopped once 25% of the maximal dose is reached. Participants on 75% of the maximal dose will be reduced to 50% of the maximal dose before reducing by 50% every 7 days. Other HF medications will be stopped as follows: MRA: reduce by 50% every 7 days then stop once 50% of maximal dose is reached; SGLT2i: stopped without titration, ARNi: reduce by 50% every 7 days then stop once 25% of the maximal dose. |
| Standard of Care Group | No intervention | –This group with continue with their heart failure medication(s) for at least 1 year. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Adult patients (age ≥18 years) with cancer therapy completed more than 6 months prior (other than hormonal therapy) and no plan for further cancer treatments with potential risk for CTRCD.
- Prior cancer therapy with anthracyclines and/ or HER2-targeted therapy.
- Prior asymptomatic, moderate to severe CTRCD, defined using the ESC/ICOS criteria (MODERATE: ≥10% drop in LVEF from baseline to 40% to 49.9% OR <10% drop to 40-49.9% with a reduction in GLS by >15% or new abnormal Troponin I/T or NT-proBNP or SEVERE: new LVEF reduction to <40% from normal baseline LVEF), diagnosed within 1 year of completing potentially cardiotoxic cancer therapy.
- Current use of ≥1 HF medication started for CTRCD for at least 6 months with LVEF ≥50% by recently performed (≤6 months) echocardiogram, normal sex and age adjusted NT-proBNP or BNP ≤97.5th Centile, and no symptoms attributable to HF.
- Reference ranges for NT-proBNP and BNP by age and sex:
Key exclusion criteria (7 listed)
- Indication for continuation of HF medications i.e., ongoing HF symptoms, chronic kidney disease (CKD), vascular disease, atrial or ventricular arrythmias, other (note: participants with hypertension pre-CTRCD will continue their antihypertensive as only medication started for CTRCD will be ceased).
- Contraindications for CMR (e.g., MRI non-compatible implanted pacemakers).
- Patients with cardiac devices i.e. defibrillator, CRT, pacemaker, etc.
- Continued use of loop diuretic therapy for heart failure purposes i.e., furosemide.
- Life expectancy <1 year or metastatic disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stopping Heart Failure Medication(s)This group will stop their heart failure medication(s) under the supervision of the study team. | Other | Stop Group |
Primary outcome
Cancer Therapy Related Cardiac Dysfunction Relapse
Time frame: 1 year
To compare the proportion of those that develop by 1 year of follow-up one or both of the following (i) left ventricular ejection fraction <50% and an absolute decline of >5% from baseline by cardiac magnetic resonance (CMR) (ii) new heart failure signs (at least two physical findings or one physical finding and one laboratory finding) AND symptoms (at least one) with the initiation of qualifying heart failure therapy.
11 secondary outcomes
Dichotomized Primary Outcome
Time frame: 1 year
Moderate to severe CTRCD by 1 year
Time frame: 1 year
Changes in cardiac magnetic resonance parameters
Time frame: 1 year
Left ventricular diastolic function
Time frame: 1 year
Non-adherence of heart failure medication(s)
Time frame: 1 year
N-terminal pro B-type Natriuretic Peptide (NT-pro BNP)
Time frame: 1 year
Changes in quality of life score
Time frame: 1 year
Cost effectiveness analysis
Time frame: 1 year
Proportion of participants developing the primary outcome by whether they developed moderate versus severe CTRCD at original diagnosis
Time frame: 1 year
Incidence of novel biomarkers and genomic factors that may determine the risk of developing the primary endpoint
Time frame: 1 year
Proportion of participants developing the primary outcome stratified by natriuretic peptides thresholds.
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
14 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Stopping Heart Failure Medication(s) in people with Heart Failure and Cardiotoxicity, run by Dinesh Thavendiranathan at 14 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in Canada, United Kingdom, United States, Australia, Poland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paaladinesh Thavendiranathan, MD (416-340-5326, dinesh.thavendiranathan@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cancer Therapy Related Cardiac Dysfunction Relapse (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.